Lexicon Pharmaceuticals
LXRX
109 hedge funds and large institutions have $662M invested in Lexicon Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 29 increasing their positions, 35 reducing their positions, and 19 closing their positions.
14% more capital invested
Capital invested by funds: $582M → $662M (+$80M)
0.68% more ownership
Funds ownership: 98.34% → 99.02% (+0.68%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 121 → 109 (-12)
17% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 35
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
67% less call options, than puts
Call options by funds: $939K | Put options by funds: $2.87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 4 |
First Manhattan
New York
|
+$1.21M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.33M |
| 2 |
SGA
Sector Gamma AS
Oslo,
Norway
|
-$2.09M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.02M |
| 4 |
AIM
Assured Investment Management
New York
|
-$611K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$569K |
LXRX Hedge Fund Activity: Q2 2019 in Review
109 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2019, worth a combined $662M — up 14% from $582M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LXRX and 10 opened new positions — a net loss of 9 holders — while 35 trimmed existing stakes and 29 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $8.86M. The largest seller was Fidelity Investments, cutting an estimated $5.33M.
- 109 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2019, down from 121 in Q1 2019.
- Funds reported $662M of Lexicon Pharmaceuticals stock for Q2 2019, up 14% quarter-over-quarter.
- 10 funds opened new Lexicon Pharmaceuticals positions in Q2 2019 and 19 closed out, a net change of -9 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2019 was Opaleye Management, an estimated $8.86M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $5.33M sold.
Based on aggregated 13F filings for Q2 2019.